Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.